secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001104659-26-026409
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Therapeutics raises $7.8M in registered direct offering and amends prior warrants
--------------------------------------------------------------------------------

- Sold 2,480,294 common shares and pre-funded warrants for 2,020,491 shares at combined $1.739/unit, plus accompanying warrants.
- Gross proceeds ~$7.8M; placement agent fees 6% cash plus 180,031 warrants at $2.0175.
- Warrant amendment reduces exercise price to $1.614 on 1,385,083 prior warrants and extends term to 5 years; investor paid ~$173k.
- Proceeds used for working capital and general corporate purposes.
- Offering closed March 11, 2026; common stock trades on Nasdaq under BTAI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/0001104659-26-026409-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926026409/tm268136d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-026409

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer